Histology-based Target Validation
Tartu/Munich - Histology-based target validation is the focus of a recently forged co-operation between German Xantos Biomedicine AG, Munich, and Applied Phenomics LLC, a privately-held clinical genomics company from Tartu, Estonia. Applied Phenomics will provide Xantos with its methodological base and clinical genomics resources for the validation of novel targets identified using Xantos' cell-based screening approach.
“Our combination of state-of-the-art molecular biology, clinical pathology expertise and research-grade ethically sound tissue samples forms a solid basis for validation of targets identified in in vitro screens,” said Dr. Tambet Teesalu, CEO at Applied Phenomics. Xantos uses its Xantoscreen™ technology to discover and functionally validate novel targets on a genome-wide basis. In the framework of the collaboration, Applied Phenomics uses its Phenomax™ tissue arrays for optimization of anti-target immunostaining in normal tissues, and performs target immu-nolocalization in tumor samples under optimized conditions.
This is complemented with in situ hybridization studies and interpreted in the context of immuno-stainings with selected diagnostic antibodies from the Applied Phenomics stock.